Shots:

• Symbiosis will provide AstraZeneca access to its sterile vaccine drug product manufacturing capacity for clinical trial supply
• The agreement follows AstraZeneca’s licensing agreement with the University of Oxford for the global development- manufacturing- and distribution of the AZD1222 vaccine candidate. The vaccine candidate is currently in clinical trials at multiple sites in the UK
•  Symbiosis will deploy its expertise and competitive strengths to accelerate the development of AstraZeneca’s vaccine and added value to the project

Click here to read full press release/ article 

Ref: Symbiosis | Image: AstraZenca